2025年欧洲肿瘤内科学会(ESMO)大会于当地时间10月17日至21日在德国柏林隆重召开。本次大会,来自江苏省人民医院黄香教授代表研究团队报告了一项瑞康曲妥珠单抗(SHR-A1811)联合帕妥珠单抗治疗HER2+不可切除/转移性乳腺癌的Ib/II期研究(536MO,Leading PI:殷咏梅教授)。该研究结果显示1,4.8 mg/kg瑞康曲妥珠单抗联合帕妥珠单抗客观缓解率(ORR)为86.4%...
Source Link2025年欧洲肿瘤内科学会(ESMO)大会于当地时间10月17日至21日在德国柏林隆重召开。本次大会,来自江苏省人民医院黄香教授代表研究团队报告了一项瑞康曲妥珠单抗(SHR-A1811)联合帕妥珠单抗治疗HER2+不可切除/转移性乳腺癌的Ib/II期研究(536MO,Leading PI:殷咏梅教授)。该研究结果显示1,4.8 mg/kg瑞康曲妥珠单抗联合帕妥珠单抗客观缓解率(ORR)为86.4%...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.